https://www.thebodypro.com/category/atazanavir-reyataz/tag/ias-international-aids-society-conference
Atazanavir (Reyataz)

IAS (International AIDS Society) Conference

The Latest

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study Img

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study

Atazanvir/ritonavir at 200/100 mg was found to be non-inferior to atazanvir/ritonavir at 300/100 mg, according to study results presented at IAS 2015.

HIV Antiretroviral Study Highlights From IAS 2015 Img

HIV Antiretroviral Study Highlights From IAS 2015

We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.

Promo Image

Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests

Patients taking Boehringer Ingelheim's HIV drug Viramune have a lower risk of developing cardiovascular disease than those taking Bristol-Myers Squibb's treatment, Reyataz, according to a study released on Monday at the 5th International AIDS Society...

Promo Image

ATAZIP: Switching Away From Lopinavir/Ritonavir

Switching between protease inhibitors (PIs) may lead to improved dosing frequency, better management of gastrointestinal and lipid toxicity and a reduction in ritonavir (RTV, Norvir) exposure levels. The SWAN study1 was the largest study to evaluate ...